137
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Narcolepsy Type 1: A Remitting Disease? An Unusual Case Report

, , , &
Pages 1669-1673 | Published online: 24 Sep 2021

References

  • Kornum BR. Narcolepsy type 1: what have we learned from immunology? Sleep. 2020;43:zsaa055.
  • Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3(1):16100. doi:10.1038/nrdp.2016.100
  • Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(10):43. doi:10.1007/s11940-016-0429-y
  • Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519–539.
  • Barker EC, Flygare J, Paruthi S, et al. Living with narcolepsy: current management strategies, future prospects, and overlooked real-life concerns. Nat Sci Sleep. 2020;12:453–466. doi:10.2147/NSS.S162762
  • Furuta H, Thorpy MJ, Temple HM. Comparison in symptoms between aged and younger patients with narcolepsy. Psychiatry Clin Neurosci. 2001;55(3):241–242. doi:10.1046/j.1440-1819.2001.00841.x
  • American Academy of Sleep Medicine. International Classification of Sleep Disorders. Darien, IL: American Academy of Sleep Medicine; 2014.
  • Taddei RN, Werth E, Poryazova R, Baumann CR, Valko PO. Diagnostic delay in narcolepsy type 1: combining the patients’ and the doctors’ perspectives. J Sleep Res. 2016;25(6):709–715. doi:10.1111/jsr.12420
  • Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029–2033. doi:10.1212/WNL.57.11.2029
  • Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13–18. doi:10.1016/j.sleep.2016.04.004
  • de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother. 2019;20(5):483–486. doi:10.1080/14656566.2018.1561861
  • Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med. 2010;11(1):93–95. doi:10.1016/j.sleep.2009.02.009
  • Dauvilliers Y, Gosselin A, Paquet J, et al. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology. 2004;62(1):46–50. doi:10.1212/01.WNL.0000101725.34089.1E
  • Desforges JF, Aldrich,MS. Narcolepsy. N Engl J Med. 1990;323(6):389–394. doi:10.1056/NEJM199008093230606
  • Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol. 2003;114(11):2000–2017. doi:10.1016/S1388-2457(03)00203-7
  • Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499–511. doi:10.1016/S0140-6736(07)60237-2
  • Dauvilliers Y, Barateau L. Narcolepsy and other central hypersomnias. Continuum. 2017;23(4, Sleep Neurology):989–1004.
  • Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand. 1975;52(5):337–353. doi:10.1111/j.1600-0404.1975.tb05830.x
  • Almeneessier AS, Alballa NS, Alsalman B, Alessie S, Olaish AH, BaHammam AS. A 10-year Longitudinal Observational Study of cataplexy in a cohort of narcolepsy type 1 patients. Nat Sci Sleep. 2019;11:231–239. doi:10.2147/NSS.S229105
  • Kim T, Lee JH, Lee CS, Yoon IY. Different fates of excessive daytime sleepiness: survival analysis for remission. Acta Neurol Scand. 2016;134(1):35–41. doi:10.1111/ane.12504
  • Pizza F, Franceschini C, Peltola H, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136(12):3787–3795. doi:10.1093/brain/awt277
  • Huang Y-S, Guilleminault C, Lin C-H, Chen C-H, Chin W-C, Chen T-S. Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: a 5-year follow-up study. J Sleep Res. 2018;27(5):e12700. doi:10.1111/jsr.12700
  • Um YH, Kim T-W, Jeong J-H, et al. A Longitudinal Follow-Up Study on multiple sleep latency test and body mass index of patients with narcolepsy type 1 in Korea. J Clin Sleep Med. 2017;13(12):1441–1444. doi:10.5664/jcsm.6844
  • Büchele F, Baumann CR, Poryazova R, Werth E, Valko PO. Remitting narcolepsy? Longitudinal observations in a hypocretin-deficient cohort. Sleep. 2018;41:9. doi:10.1093/sleep/zsy118
  • Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14(3):318–328. doi:10.1016/S1474-4422(14)70218-2
  • Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56(6):905–908. doi:10.1002/ana.20339
  • Martínez-Orozco FJ, Vicario JL, Villalibre-Valderrey I, et al. Narcolepsy with cataplexy and comorbid immunopathological diseases. J Sleep Res. 2014;23(4):414–419. doi:10.1111/jsr.12143
  • Ruppert E, Zagala H, Chambe J, et al. Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. Behav Neurol. 2018;2018:1671072.
  • Saper CB. Restoration: potential for compensatory changes in numbers of neurons in adult human brain: restoration. Ann Neurol. 2013;74(6):762–764. doi:10.1002/ana.24039
  • Quinnell T, Wozniak D. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51–61. doi:10.2147/NSS.S56077